Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors

Cardiovasc Res. 2015 Jan 1;105(1):118-28. doi: 10.1093/cvr/cvu240. Epub 2014 Nov 19.

Abstract

Aims: The ryanodine receptor (RyR2) is an intracellular Ca(2+) release channel essential for cardiac excitation-contraction coupling. Abnormal RyR2 channel function results in the generation of arrhythmias and sudden cardiac death. The present study was undertaken to investigate the mechanistic basis of RyR2 dysfunction in inherited arrhythmogenic cardiac disease.

Methods and results: We present several lines of complementary evidence, indicating that the arrhythmia-associated L433P mutation disrupts RyR2 N-terminus self-association. A combination of yeast two-hybrid, co-immunoprecipitation, and chemical cross-linking assays collectively demonstrate that a RyR2 N-terminal fragment carrying the L433P mutation displays substantially reduced self-interaction compared with wild type. Moreover, sucrose density gradient centrifugation reveals that the L433P mutation impairs tetramerization of the full-length channel. [(3)H]Ryanodine-binding assays demonstrate that disrupted N-terminal intersubunit interactions within RyR2(L433P) confer an altered sensitivity to Ca(2+) activation. Calcium imaging of RyR2(L433P)-expressing cells reveals substantially prolonged Ca(2+) transients and reduced Ca(2+) store content indicating defective channel closure. Importantly, dantrolene treatment reverses the L433P mutation-induced impairment and restores channel function.

Conclusion: The N-terminus domain constitutes an important structural determinant for the functional oligomerization of RyR2. Our findings are consistent with defective N-terminus self-association as a molecular mechanism underlying RyR2 channel deregulation in inherited arrhythmogenic cardiac disease. Significantly, the therapeutic action of dantrolene may occur via the restoration of normal RyR2 N-terminal intersubunit interactions.

Keywords: arrhythmias; dantrolene; excitation–contraction coupling; oligomerization; ryanodine receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-Arrhythmia Agents / pharmacology
  • Arrhythmias, Cardiac / drug therapy*
  • Arrhythmias, Cardiac / genetics
  • Arrhythmias, Cardiac / metabolism
  • Arrhythmogenic Right Ventricular Dysplasia / etiology
  • Arrhythmogenic Right Ventricular Dysplasia / genetics
  • Arrhythmogenic Right Ventricular Dysplasia / metabolism
  • Calcium Signaling / drug effects
  • Dantrolene / pharmacology*
  • HEK293 Cells
  • Heart Failure / etiology
  • Heart Failure / genetics
  • Heart Failure / metabolism
  • Humans
  • Models, Cardiovascular
  • Mutagenesis, Site-Directed
  • Mutant Proteins / chemistry
  • Mutant Proteins / genetics*
  • Mutant Proteins / metabolism*
  • Myocardium / metabolism
  • Protein Interaction Domains and Motifs / drug effects
  • Protein Multimerization / drug effects
  • Protein Stability / drug effects
  • Ryanodine Receptor Calcium Release Channel / chemistry
  • Ryanodine Receptor Calcium Release Channel / genetics*
  • Ryanodine Receptor Calcium Release Channel / metabolism*
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / genetics
  • Tachycardia, Ventricular / metabolism

Substances

  • Anti-Arrhythmia Agents
  • Mutant Proteins
  • Ryanodine Receptor Calcium Release Channel
  • Dantrolene

Supplementary concepts

  • Arrhythmogenic Right Ventricular Dysplasia, Familial, 2
  • Polymorphic catecholergic ventricular tachycardia